Given the rapid pace of HCV drug development, the HCV DrAG Drug Resistance Slidesets (ResisSS) have been updated with recent data from EASL 2013 regarding interferon-containing and interferon-free regimens.

1.  HCV Lifecycle, Drug Targets, and Mechanisms of Action   | PPT | PDF |
2.  HCV Resistance Barriers, Selection and Monitoring of Resistance | PPT | PDF |
3.  HCV Treatment Strategies to Reduce Drug Resistance        | PPT | PDF |

Recognizing the need for HCV drug resistance education, the members of the Forum for Collaborative HIV Research's HCV Drug Development Advisory Group (academicians, clinicians, researchers, industry partners and patient advocates) have contributed to a slide deck explaining drug resistance in HCV, its consequences, as well as mitigating its impact. 

The educational slidesets’ intended audience ranges from health care providers evaluating, diagnosing and treating HCV, to patients who want to learn about the disease and treatment options, and advocates who may use the slides in their community education outreach efforts. 

These slides may be used in the user's own non-commercial presentations, but kindly do not change content and attribution. We also ask that the slides not be published or posted online without permission from the Forum for Collaborative HIV Research.

For comments or more information, please contact Nivedha Panneer at npanneer at hivforum.org